PTPRT epigenetic silencing defines lung cancer with STAT3 activation and can direct STAT3 targeted therapies

References

• Cancer Facts and. Figures. American Cancer Society; 2015.
   Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.
   PubMed Web of Science ®Google Scholar
• American cancer society cancer facts and figures. Atlanta, GA; 2016.
   Google Scholar
• David EA, Daly ME, Li CS, et al. Increasing rates of no treatment in advanced-stage non-small cell lung cancer patients: a propensity-matched analysis. J Thorac Oncol. 2017;12:437–445.
   Google Scholar
• Centers for Disease Control and Prevention National Center for Health Statistics CDC WONDER On-line database, compiled from compressed mortality file 1990-2010 series 20 No. 2P. 2013.
   Google Scholar
• Vijayalakshmi R, Krishnamurthy A. Targetable “driver” mutations in non small cell lung cancer. Indian J Surg Oncol. 2011;2(3):178–188.
   PubMedGoogle Scholar
• Isla D, De Castro J, Juan O, et al. Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer. Clinicoecon Outcomes Res. 2017;9:31–38.
   PubMed Web of Science ®Google Scholar
• Fujita K, Kim YH, Yoshizawa A, et al. Concomitant T790M mutation and small-cell lung cancer transformation after acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor. Respirol Case Rep. 2017;5(1):e00206.
   PubMed Web of Science ®Google Scholar
• Wang W, Song Z, Zhang Y. A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance. Cancer Med. 2017;6(1):154–162.
   PubMed Web of Science ®Google Scholar
• Kaufman J, Stinchcombe TE. Treatment of KRAS-mutant non-small cell lung cancer: the end of the beginning for targeted therapies. JAMA. 2017;317(18):1835–1837.
   PubMed Web of Science ®Google Scholar
• Bowman T, Garcia R, Turkson J, et al. STATs in oncogenesis. Oncogene. 2000;19(21):2474–2488.
   PubMed Web of Science ®Google Scholar
• Harada D, Takigawa N, Kiura K. The role of STAT3 in non-small cell lung cancer. Cancers (Basel). 2014;6(2):708–722.
   PubMed Web of Science ®Google Scholar
• Grabner B, Schramek D, Mueller KM, et al. Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. Nat Commun. 2015;6:6285.
   PubMed Web of Science ®Google Scholar
• Song L, Turkson J, Karras JG, et al. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene. 2003;22(27):4150–4165.
   PubMed Web of Science ®Google Scholar
• Darnell JE Jr. STATs and gene regulation. Science. 1997;277(5332):1630–1635.
   PubMed Web of Science ®Google Scholar
• Liu LJ, Leung KH, Chan DS, et al. Identification of a natural product-like STAT3 dimerization inhibitor by structure-based virtual screening. Cell Death Dis. 2014;5:e1293.
   PubMed Web of Science ®Google Scholar
• Al Zaid Siddiquee K, Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res. 2008;18(2):254–267.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543–550.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489(7417):519–525.
   PubMed Web of Science ®Google Scholar
• Njatcha C, Farooqui M, Kornberg A, et al. STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non-Small Cell Lung Cancer. Mol Cancer Ther. 2018;17(9):1917–1926.
   PubMed Web of Science ®Google Scholar
• Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel). 2017;9:5.
   Web of Science ®Google Scholar
• Durant L, Watford WT, Ramos HL, et al. Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity. 2010;32(5):605–615.
   PubMed Web of Science ®Google Scholar
• Looyenga BD, Hutchings D, Cherni I, et al. STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma. PloS One. 2012;7(2):e30820.
   PubMed Web of Science ®Google Scholar
• Ward AC, editor. STAT3 inhibitors in cancer. Cancer Drug Discovery and Development;2016.
   Google Scholar
• Zhang X, Guo A, Yu J, et al. Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T. Proc Natl Acad Sci U S A. 2007;104(10):4060–4064.
   PubMed Web of Science ®Google Scholar
• Peyser ND, Freilino M, Wang L, et al. Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer. Oncogene. 2016;35(9):1163–1169.
   PubMed Web of Science ®Google Scholar
• Wang Z, Shen D, Parsons DW, et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science. 2004;304(5674):1164–1166.
   PubMed Web of Science ®Google Scholar
• Lee JW, Jeong EG, Lee SH, et al. Mutational analysis of PTPRT phosphatase domains in common human cancers. APMIS. 2007;115(1):47–51.
   PubMed Web of Science ®Google Scholar
• Lui VW, Peyser ND, Ng PK, et al. Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. Proc Natl Acad Sci U S A. 2014;111(3):1114–1119.
   PubMed Web of Science ®Google Scholar
• Laczmanska I, Karpinski P, Bebenek M, et al. Protein tyrosine phosphatase receptor-like genes are frequently hypermethylated in sporadic colorectal cancer. J Hum Genet. 2013;58(1):11–15.
   PubMed Web of Science ®Google Scholar
• R tR. A language and environment for statistical computing. Vienna, Austria: R foundation for statistical computing; 2004.
   Google Scholar
• Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5(10):R80.
   PubMed Web of Science ®Google Scholar
• Bibikova M, Barnes B, Tsan C, et al. High density DNA methylation array with single CpG site resolution. Genomics. 2011;98(4):288–295.
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1.
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–404.
   PubMed Web of Science ®Google Scholar
• Siegfried JM, Lin Y, Diergaarde B. et al. Expression of PAM50 genes in lung cancer: evidence that interactions between hormone receptors and HER2/HER3 contribute to poor outcome. Neoplasia (New York, NY). 2015;17(11):817–825.
   PubMed Web of Science ®Google Scholar
• Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002;18(11):1427–1431.
   PubMed Web of Science ®Google Scholar
• Leeman-Neill R. Prevention and treatment of head and neck cancer with natural compound inhibitors of STAT3. Doctoral Dissertation, University of Pittsburgh. PhD thesis, University of Pittsburgh 2008.
   Google Scholar
• LaPorte MG, Wang Z, Colombo R, et al. Optimization of pyrazole-containing 1,2,4-triazolo-[3,4-b]thiadiazines, a new class of STAT3 pathway inhibitors. Bioorg Med Chem Lett. 2016;26(15):3581–3585.
   PubMed Web of Science ®Google Scholar
• Johnston PA, Sen M, Hua Y, et al. HCS campaign to identify selective inhibitors of IL-6-induced STAT3 pathway activation in head and neck cancer cell lines. Assay Drug Dev Technol. 2015;13(7):356–376.
   PubMed Web of Science ®Google Scholar
• Pelosof L, Yerram S, Armstrong T, et al. GPX3 promoter methylation predicts platinum sensitivity in colorectal cancer. Epigenetics. 2017;12(7):540–550.
   PubMed Web of Science ®Google Scholar
• Kluge A, Dabir S, Vlassenbroeck I, et al. Protein inhibitor of activated STAT3 expression in lung cancer. Mol Oncol. 2011;5(3):256–264.
   PubMed Web of Science ®Google Scholar
• Chen Y, Cao Y, Yang D, et al. Increase of the therapeutic effect on non-small-cell lung cancer cells with combination treatment of shRNA against cyclin D1 and Bcl-xL in vitro. Exp Ther Med. 2012;3(2):255–260.
   PubMed Web of Science ®Google Scholar
• Johnston PA, Sen M, Hua Y, et al. High-content pSTAT3/1 imaging assays to screen for selective inhibitors of STAT3 pathway activation in head and neck cancer cell lines. Assay Drug Dev Technol. 2014;12(1):55–79.
   PubMed Web of Science ®Google Scholar
• Sen M, Johnston PA, Pollock NI, et al. Mechanism of action of selective inhibitors of IL-6 induced STAT3 pathway in head and neck cancer cell lines. J Chem Biol. 2017;10(3):129–141.
   PubMedGoogle Scholar
• Chan BA, Hughes BG. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res. 2015;4(1):36–54.
   PubMed Web of Science ®Google Scholar
• Vizoso M, Puig M, Carmona FJ, et al. Aberrant DNA methylation in non-small cell lung cancer-associated fibroblasts. Carcinogenesis. 2015;36(12):1453–1463.
   PubMed Web of Science ®Google Scholar
• Koinis F, Kotsakis A, Georgoulias V. Small cell lung cancer (SCLC): no treatment advances in recent years. Transl Lung Cancer Res. 2016;5(1):39–50.
   PubMed Web of Science ®Google Scholar
• Rocha-Lima CM, Raez LE. Erlotinib (tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer. P T. 2009;34(10):554–564.
   PubMedGoogle Scholar
• Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev. 2009;9(1):28–39.
   Google Scholar
• Sequist LV, Bell DW, Lynch TJ, et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol. 2007;25(5):587–595.
   PubMed Web of Science ®Google Scholar
• Pan ZY, Jiang ZS, Ouyang HQ. Study of the methylation patterns of the EGFR gene promoter in non-small cell lung cancer. Genet Mol Res. 2015;14(3):9813–9820.
   PubMed Web of Science ®Google Scholar
• Brugger W, Thomas M. EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatment. Lung Cancer. 2012;77(1):2–8.
   PubMed Web of Science ®Google Scholar
• Sen M, Thomas SM, Kim S, et al. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov. 2012;2(8):694–705.
   PubMed Web of Science ®Google Scholar
• Timp W, Feinberg AP. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev. 2013;13(7):497–510.
   Google Scholar
• Liu Z, Zhang J, Gao Y, et al. Large-scale characterization of DNA methylation changes in human gastric carcinomas with and without metastasis. Clin Cancer Res off J Am Assoc Cancer Res. 2014;20(17):4598–4612.
   PubMed Web of Science ®Google Scholar